GE HealthCare Secures EU Approval for MINItrace Magni Cyclotron

Key Facts

1GE HealthCare secured the CE Mark certification for its MINItrace Magni cyclotron, designed for radioisotope production.

GE HealthCare Technologies Inc secured the CE Mark certification for its MINItrace Magni cyclotron, a device designed for radioisotope production. Zacks reported that this regulatory approval enables the company to expand its Copper-64 production capabilities, strengthening its PET imaging and theranostics portfolio in Europe.

The approval aims to enhance the local production of medical isotopes to meet growing demand for advanced imaging technologies. GEHC closed at $69.76 on October 19, 2026, with the stock reaching a session high of $70.08 and a low of $69.06 on that date.